ACC Results Recap Part III: RADIANCE-HTM SOLO Results Support ReCor’s Renal Denervation System
Executive Summary
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the third of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including the final results of the MOMENTUM 3 trial of Abbott’s HeartMate 3 left-ventricular assist device and six-month results from the RADIANCE-HTN SOLO trial of ReCor’s Paradise renal denervation system, and more. Check out Part I and Part II of our ACC Results Recap.
You may also be interested in...
Cardio Catch-Up: Medtronic Plans To Buy Cathworks, Edwards Delays Evoque CE Mark, And More
Part II of highlights the cardiovascular tech sectors includes news from Medtronic, Edwards Lifesciences, and Abbott, plus a look at the upcoming TCT Conference in Boston.
HeartFlow Wants To Accelerate Adoption Of AI-Powered Heart Disease Test With $2.4Bn SPAC Deal
SPAC Longview Acquisition Corp. said it will take Heartflow public in a transaction that will provide the combined company with $400m in cash.
CMS Updates Medicare Coverage For LVADs, Artificial Hearts
Patient selection criteria will be the key to allowing CMS coverage of left ventricular assist devices (LVADs) when there is no longer a coverage with evidence development requirement, the US agency wrote.